首页> 外文期刊>Clinical and vaccine immunology: CVI >Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age
【24h】

Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age

机译:在12个月龄时,联合使用C型脑膜炎球菌血清群C和b型流感嗜血杆菌结合疫苗和7价肺炎球菌结合疫苗,麻疹,腮腺炎和风疹疫苗的安全性和免疫原性

获取原文
           

摘要

The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this regimen compared with separate administration of the conjugate vaccines. Children were randomized to receive MCC/Hib vaccine alone followed 1 month later by PCV7 with MMR vaccine or to receive all three vaccines concomitantly. Immunogenicity endpoints were MCC serum bactericidal antibody (SBA) titers of ≥8, Hib-polyribosylribitol phosphate (PRP) IgG antibody concentrations of ≥0.15 μg/ml, PCV serotype-specific IgG concentrations of ≥0.35 μg/ml, measles and mumps IgG concentrations of >120 arbitrary units (AU)/ml, and rubella IgG concentrations of ≥11 AU/ml. For safety assessment, the proportions of children with erythema, swelling, or tenderness at site of injection or fever or other systemic symptoms for 7 days after immunization were compared between regimens. No adverse consequences for either safety or immunogenicity were demonstrated when MCC/Hib vaccine was given concomitantly with PCV and MMR vaccine at 12 months of age or separately at 12 and 13 months of age. Any small differences in immunogenicity were largely in the direction of a higher response when all three vaccines were given concomitantly. For systemic symptoms, there was no evidence of an additive effect; rather, any differences between schedules showed benefit from the concomitant administration of all three vaccines, such as lower overall proportions with postvaccination fevers. The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age.
机译:乙型脑膜炎球菌血清群C结合物(MCC)/ b流感嗜血杆菌(emb)(Hib)疫苗与肺炎球菌结合物疫苗(PCV7)和麻疹,腮腺炎和风疹(MMR)疫苗在12个月时共同给药与结合疫苗分开给药相比,研究了年龄以评估该方案的安全性和免疫原性。儿童被随机分配为单独接受MCC / Hib疫苗,随后1个月后接受PCV7和MMR疫苗的接种,或同时接受全部三种疫苗的接种。免疫原性终点是MCC血清杀菌抗体(SBA)滴度≥8,Hib-聚核糖核糖醇磷酸(PRP)IgG抗体浓度≥0.15μg/ ml,PCV血清型特异性IgG浓度≥0.35μg/ ml,麻疹和腮腺炎IgG浓度> 120个任意单位(AU)/ ml,风疹IgG浓度≥11AU / ml。为了进行安全性评估,比较了两种方案免疫后7天内有注射,发烧或其他全身症状的部位出现红斑,肿胀或压痛的儿童的比例。当MCC / Hib疫苗与PCV和MMR疫苗在12个月大时或分别在12个月和13个月大时同时接种时,未显示出对安全性或免疫原性的不利影响。当同时给予所有三种疫苗时,免疫原性的任何细微差异主要是在更高的应答方向上。对于全身症状,没有证据表明有累加作用。相反,时间表之间的任何差异都表明,同时使用所有三种疫苗都受益,例如接种疫苗后发烧的总体比例降低。现在,英国婴儿免疫时间表建议,这三种疫苗可在12至13个月大时一次就诊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号